Cineplex (TSX:CGX) Is Selling a High-Yield Bond as Investors Bank on Recovery

Cineplex stock has rebounded following the company’s sale of its high-yield bonds. Investors are positioning for a recovery post-pandemic after Canada’s nationwide vaccination campaign.

| More on:
Bonds

Image source: Getty Images

Through no fault of management, Canada’s largest chain of movie theatres suffered a 74.9% drop in total revenue in 2020 compared to 2019. All business segments’ revenues (film & entertainment content, media, and amusement & leisure) fell significantly. Cineplex (TSX:CGX) Store, however, reported a 39% growth in total registered users.

Management suspended dividends and curbed capital expenditures in April 2020 to conserve cash. The shares of the former dividend king sunk to as low as $4.54 on October 14, 2020.  In Q4 2020, the company’s net cash burn was approximately $24.8 million per month. As of February 26, 2021, Cineplex trades at $13.82 per share, or 59% lower than it was a year ago.

Fortunately, despite the total disruption of business operations, Cineplex still had access to capital. Management successfully sold $250 million worth of unrated bonds recently. The company’s blowout bonds will mature in 2026. Cineplex’s second-lien, secured, senior bonds yield 7.5% compared to the average high-yield bond’s offer of 3.5%.

Economic recovery trade

Investors around the world lined up to purchase Cineplex bonds. Thus far, deal arrangers said the preliminary indications of interest are roughly $1 billion. The garnered orders represent five times the deal size. Cineplex planned was to raise a minimum $200 million by the end of March 2021. It would sell bonds to meet conditions for a covenant waiver agreed to with its existing lenders.

Bank of Montreal and Scotiabank are the bond sale managers. It appears the interested parties are positioning for a post-pandemic reopening. Also, the strong demand indicates that investors seek to play the economic recovery trade. They are banking on Canada’s execution of its vaccination campaign.

Six million doses in March

The federal government targets the vaccination of Canada’s entire population once vaccine supply is continuous and in large enough quantities. Meanwhile, most provinces and territories have plans to go about the vaccine rollouts and who are the priority groups.

According to Howard Njoo, Canada’s deputy chief public health officer, around 2.9% of Canadians have received at least one vaccine dose as of February 2021. Health officials expect the percentage to increase significantly throughout March. About six million doses from Pfizer and Moderna combined should arrive in Canada by the end of March.

Scrapped deal

Cineplex filed a suit against Cineworld Group PLC suit in the Ontario Superior Court in July 2020. The company is seeking damages after the London-based theatre operator walked out from a $2.8 billion deal to acquire Cineplex, citing breach of contract.

Aside from damages, the Canadian movie theatre chain also seeks compensation for the $664 million in debt and transaction expenses. Cineworld would have paid the amount had the deal been successful. Cineworld filed a Statement of Defence and Counterclaim that denies Cineplex’s claims. The schedule of the trial is September 2021.

Salvation and risks

The deal with Cineworld was supposed to be the salvation for Cineplex that was already experiencing declining attendance in 2019. Now, the merger is off due to COVID-19. The transaction would have provided Cineplex about 12-18 months of operating liquidity.

With the bond sale, Cineplex would have ample liquidity to ride out the storm. However, investors face risk if vaccines don’t roll out in time and moviegoers aren’t back to theatres in 2022.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. David Gardner owns shares of Moderna Inc. The Motley Fool recommends BANK OF NOVA SCOTIA, CINEPLEX INC., and Moderna Inc.

More on Coronavirus

Paper airplanes flying on blue sky with form of growing graph
Coronavirus

Air Canada Stock Is Starting to Get Ridiculously Oversold

Air Canada (TSX:AC) has been beaten down to absurd lows.

Read more »

Aircraft wing plane
Coronavirus

Should You Buy Air Canada Stock While it’s Below $18?

Air Canada (TSX:AC) stock is below $18. Should you invest?

Read more »

Illustration of data, cloud computing and microchips
Stocks for Beginners

3 Canadian Stocks That Could Still Double in 2024

These three Canadians stocks have been huge winners already in 2024, but still have room to double again in the…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Can Air Canada Stock Recover in 2024?

Air Canada (TSX:AC) stock remains close to its COVID-19 era lows, even though its business has recovered.

Read more »

A airplane sits on a runway.
Coronavirus

3 Things to Know About Air Canada Stock Before You Buy

Air Canada stock continues to hover below $20 despite the sharp rise in travel demand seen across the industry. What's…

Read more »

tech and analysis
Stocks for Beginners

If You Invested $1,000 in WELL Health in 2019, Here is What It’s Worth Now

WELL stock (TSX:WELL) has fallen pretty dramatically from all-time highs, but what if you bought just before the rise? Should…

Read more »

Hand arranging wood block stacking as step stair with arrow up.
Coronavirus

2 Pandemic Stocks That Are Still Rising, and 1 Offering a Major Deal

There are some pandemic stocks that crashed and burned, while others have made a massive comeback. And this one stock…

Read more »

Dad and son having fun outdoor. Healthy living concept
Dividend Stocks

1 Growth Stock Down 15.8% to Buy Right Now

A growth stock is well-positioned to resume its upward momentum in 2024 following its strong financial results and business momentum.

Read more »